Trials / Completed
CompletedNCT03122444
Imipramine on ER+ve and Triple Negative Breast Cancer
A Pre-Surgical Window of Opportunity Trial Investigating the Effect of Imipramine on Previously Untreated Breast Cancer (CTMS# 17-0037)
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- The University of Texas Health Science Center at San Antonio · Academic / Other
- Sex
- All
- Age
- 18 Years – 71 Years
- Healthy volunteers
- Not accepted
Summary
Comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.
Detailed description
This will be a single arm, non-randomized, pre-surgical clinical trial of women with newly diagnosed triple negative breast cancer comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imipramine | Imipramine will be given daily for 21-30 days. |
Timeline
- Start date
- 2019-07-05
- Primary completion
- 2022-03-01
- Completion
- 2022-05-01
- First posted
- 2017-04-20
- Last updated
- 2023-06-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03122444. Inclusion in this directory is not an endorsement.